Cagrilintide

Amylin is a beta-cell hormone released together with insulin; cagrilintide is its long-acting, chemically altered version. The modifications lift the half-life into a range that allowed weekly intervals in studies.

Why the molecule has a role of its own in research:

• Separate signaling route: cagrilintide engages amylin and calcitonin receptors in the brainstem and hypothalamus, bypassing the GLP-1 axis.
• Preclinical findings: longer satiety, lower food intake, slower gastric emptying.
• Isolated view: as a single agent it serves to study the amylin pathway without GLP-1 involvement.
• Combination: most attention, though, goes to its pairing with semaglutide. The two pathways show additive effects, and in the phase 2 trials by Lau et al., the reduction with the combination exceeded semaglutide alone; the pre-mixed version is called CagriSema.

What the development work describes: a stable, lipidated amylin analogue selected for clinical development after structure-activity studies. The phase 1b data on the combination with semaglutide 2.4 mg report a half-life between 159 and 195 hours; after 20 weeks, 17.1 percent weight loss stood against 9.8 percent with semaglutide plus placebo. The natural template, amylin, consists of 37 amino acids and acts through receptors built from a core receptor plus RAMP proteins, chiefly in the circumventricular organs. If you want to dig deeper, the sources below hold the phase 2 mono trial, the phase 1b combination trial, the development paper and a review of amylin.

For cagrilintide, the studies describe an overall good tolerability profile. The gut dominates here too, but in the trials the effects tend to be milder than under GLP-1 agonists.

• Stomach and bowel: nausea, vomiting, diarrhea and constipation are named most often, mainly early on and with rapid dose increases; slow titration lowered the rate.
• Fluids: the prolonged satiety reduces food and fluid intake in the studies, and the literature describes a raised risk of dehydration.
• Muscle and injection site: part of the weight lost is muscle mass, and mild local irritation is documented.
• Evidence: because the molecule is mostly studied together with semaglutide, robust human data on long-term use on its own are limited.

This summary is no substitute for medical advice.

• Once-weekly cagrilintide for weight management in people with overweight and obesity - the 26-week phase 2 trial, 706 participants, cagrilintide on its own.
• Cagrilintide with semaglutide 2.4 mg: randomised phase 1b trial - the combination trial with 95 participants that supplied the half-life and the 20-week figures.
• Development of Cagrilintide, a Long-Acting Amylin Analogue - the development paper with the structure-activity work behind the molecule's selection.
• Amylin: Pharmacology, Physiology, and Clinical Potential - review of the natural hormone, its receptors and its role in glucose and energy metabolism.